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ABSTRACT 
The role of hCG as a stimulator of the human thyroid has been a 
subject of controversy, because discrepant results have been obtained in 
different in vitro assays. In an attempt to explain the variation observed 
in the thyroid response to hCG, we investigated the ability of hCG and 
that of its isoforms and glycosylation variants to inhibit [iz51]bovine (b) 
TSH binding and stimulate adenylate cyclase in two clones, JPO9 and 
JP26, of Chinese hamster ovary cells stably transfected with the human 
TSH receptor (hTSHr). The two clones differed with respect to the num- 
ber of hTSHr expressed per cell (34,000 in JPO9 and 2,000 in JP26 cells). 
Both responded extremely well to bTSH, the cAMP response to 0.001 
III/L. bTSH was distinguishable from basal values. Interestingly, JPO9 
cells were readily stimulated by hCG (20-100 mg&; 0.52-2.6 x 10-s 
mol/L) to release CAMP, whereas JP26 cells showed little if any response. 
Also. CAMP stimulation ureduced bv asialo-hCG was la-fold in JPO9 
cells’and only 4-fold in JP26 cells compared to 45- and 67-fold stimula- 
tions by bTSH, respectively. Stimulation by asialo-hCG was approxi- 
mately 30% that of bTSH in JPO9 cells, but less than 6% in JP26 cells. 
When assessing the thyrotropic activity of the microheterogeneous iso- 
forms of hCG, more alkaline p1 forms were found to be more active than 
those of a more acidic p1 regardless of whether they were derived from 
normal or molar pregnancy urine. Further studies with hCG, asialo- 
hCG, asialoagalacto-hCG, and deglycosylated hCG revealed that re- 
moval of sialic acid caused a marked increase in both its a&&y for 
hTSHr and its cAMPreleasing potency, whereas removal of further 
carbohydrate, although it slightly enhanced receptor binding, was det- 
rimental to adenylate cyclase activation. 
In conclusion, differences in hTSHr expression may cause a vari- 
ation in the CAMP response to hCG or its glycosylation variants, as 
does the microheterogeneity of the hormone itself. These mechanisms 
may be responsible at least in part for the divergent responses of 
different cell types to hCG and render interpretation of the physio- 
logical meaning of the data obtained in recombinant receptor systems 
difficult. (J Clin Endocrinol Metab 80: 1605-1610, 1995) 
h CG exhibits considerable homology in its structure with human TSH (hTSH) as does CG/LH receptor with TSH 
receptor (TSHr) (l-3). As a result, this hormone has been 
reported to possess significant thyrotropic activity, which 
may be clinically relevant in hyperthyroidism of pregnant 
women and patients with trophoblastic tumors (4). How- 
ever, its role as a thyroid stimulator has been a subject of 
controversy, because in vitro studies have shown a wide 
variation in the thyroid response to hCG (5-12). 
Therefore, to elucidate possible factors that may account for 
the variation observed in the in vitro thyroid response to hCG, 
we investigated the interaction of hCG with recombinant hu- 
man TSHr (hTSHr) expressed in Chinese hamster ovary (CHO) 
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cells. To study the variability related to hTSHr expression, we 
assessed [‘?]bTSH binding inhibition and CAMP stimulation 
induced by bTSH and hCG in two different clones of CHO- 
TSHr cells stably transfected with the hTSI-Ir. Further, to eval- 
uate the variability related to the microheterogeneity of the 
hormone itself, we assessed the thyrotropic activities of natu- 
rally occurring isoforms of hCG derived from either normal or 
molar pregnancy urine. To more precisely define the role of 
carbohydrate in this respect, the glycosylation variants, asialo- 
hCG, asialoagalacto-hCG, and deglycosylated hCG, were also 
tested for their bTSH binding-inhibiting and cAMI’-stimulating 
activities in CHO-TSHr cells. 
Materials and Methods 
Materials 
Labeled bTSH was purchased from Henning (Berlin, Germany), and 
the unlabeled hormone (-30 IU/mgl was obtained from Armour Co. 
(North Chicago, IL). Crude urinary p;egnancy hCG (-2500 ILJ/mg) was 
obtained from Averst (Rouses Point, NY). Hiehlv uurified hCG (CR123), 
”  21 
used for standardization, was supplied by the Hormone Distribution 
Program of the NIDDK (Bethesda, MD). Immobilized neuraminidase 
from Clostridium perfringens (type VI-A) and 6-galactosidase were pur- 
chased from Sigma Chemical Co. (Deisenhofen, Germany); cell culture 
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reagents were obtained from Gibco-BRL (Eggenstein, Germany) and 
Seromed (Berlin, Germany); and CAMP RIA kits were purchased from 
Amersham (Braunschweig, Germany). 
Two clones, JPO9 and JP26, of CHO cells stably transfected with com- 
plementary DNA for the hTSHr were kindly provided by Drs. Maenhaut 
and Vassart, University of Brussels (Brussels, Belgium) (13, 14). 
Preparation of hCG, hCG isoforms, and carbohydrate- 
modified variants of hCG 
Highly purified hCG (-12,000 IU/mg) was isolated from crude preg- 
nancy hCG by sequential chromatography on columns of DEAE-52 and 
Sephadex G-100 (Pharmacia, Freiburg, Germany), as described previ- 
ously (15). Crude molar hCG extracted from the urine of eight euthyroid 
patients with hydatidiform moles was pooled and purified using the 
procedure employed for purification of hCG. 
The isoforms of hCG were prepared by chromatography of purified 
pregnancy (hCGp) or molar hCG (hCGm) on a column of Mono S 5/5 
(Pharmacia, Freiburg, Germany), combining the fractions eluted into 
three pools (pools I-III). The pools were shown by isoelectric focusing 
to comprise p1 forms of hCG ranging from 3.9-4.1 (pool I), 4.1-5 (pool 
II), and greater than 5 (pool III). 
To obtain asialo-hCG, purified hCG was desialylated by digestion 
with neuraminidase, following the protocol of van Hall et al. (161, which 
had been previously employed in our laboratory (11,15,17). Asialoaga- 
lacto-hCG was obtained by further enzymatic digestion of asialo-hCG 
with S-galactosidase (17). hCG lacking almost all of its carbohydrate 
moiety (deglycosylated hCG) was prepared by treating hCG with an- 
hydrous hydrogen fluoride, as described in detail previously (18). 
To define their purity and other properties, the hCG preparations 
were subjected to sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis (under reducing and nonreducing conditions) and analyses of 
their amino acid composition and contents of sialic acid, galactose, and 
other carbohydrates before and after treatment with the various en- 
zymes and chemicals. We also determined their immunological activ- 
ities by various immunometric assays specific for holo-hCG, free hCG8, 
hCGp core fragment, or hCGa and their abilities to inhibit [‘251JhCG 
binding to rat testicular membranes. The main results of these studies 
have been reported previously (15, 17, 18). The purity, immunological 
activity, and hCG receptor binding potency of the substances used in the 
present studies were comparable to those of the standard preparation of 
hCG (CR123). Removal of sialic acid and galactose residues was more 
than 80% complete, as measured by the calorimetric method of Warren 
(19) and the copper reduction method of Somogyi and Nelson (20), 
respectively. Deglycosylation removed 60-80% of the total carbohy- 
drate, with substantial amounts of N-acetylglucosamine and N-acetyl- 
galactosamine still remaining attached (18, 21). 
The mol wt of the hormone preparations used were estimated to be: 
bTSH, 28,000; purified hCG, 38,000; asialo-hCG, 34,500; asialoagalacto- 
hCG, 33,000; and deglycosylated hCG, 30,000. 
Cell culture 
Two clones of CHO cells stably transfected with the hTSHr (CHO- 
TSHr cells JPO9 and JP26) and the CHO wild-type cells (CHO cells), 
which served as controls, were grown in 75-cm’ culture flasks in Ham’s 
F-12 Medium containing 1 mmol/L sodium pyruvate, 100,000 IU/L 
penicillin, 100 mg/L streptomycin, 2.5 g/L amphotericin-B, and 5% fetal 
calf serum. The cells were cultured under an atmosphere of 5% COz and 
passaged every 3-4 days. 
Studies of binding to CHO-TSHr cells 
To study the binding of ‘=I-labeled bTSH, cells were transferred to 
24-well plates (-7 x lo5 cells/well) and incubated together with the 
tracer (-6,000 cpm; SA, 40,000-60,000 Ci/kg) and the respective cold 
ligands at 4 C for 24 h in modified sodium-free Hanks’ buffer supple- 
mented with 278 mmol/L sucrose and 0.1% BSA (11,18). At the end of 
the incubation period, the supematant was removed, the cells were 
washed and solubilized with 0.5 mL 1 N NaOH, and their ‘=I content 
was measured in a y-counter. Nonspecific binding was determined by 
the addition of an excess of unlabeled bTSH (500 III/L) and subtracted 
from total binding to yield specific binding values, which are shown in 
the figures. 
CAMP measurement in CHO-TSHr cells 
Cells transferred to 96-well plates (-105 cells/well) and maintained 
in culture medium for 3 days were incubated, in the presence of 1 
mmol/L 1-methyl-3-isobutylxanthine, with various concentrations of 
bTSH or the various hCG forms for 2 h at 37 C in Krebs-Ringer bicar- 
bonate buffer. The CAMP concentration was measured in an aliquot of 
the supematant by a commercially available RIA (11, 18,22). 
Isoelectric focusing 
Isoelectric focusing of hCG was carried out on a 7% acrylamide gel 
(150 X 60 X 0.48 mm; Pharmacia) containing 3% Servalyt 3-6 (Serva, 
Heidelberg, Germany) under the following conditions: 2000 V, 200 
mamp, maximum 15 watts, 10 C, 1 h. The bands were specifically stained 
with a monoclonal holo-hCG antibody, as described previously (23-25). 
Statistical methods 
For statistical comparison of data, Wilcoxon’s test for unpaired ob- 
servations was used. 
Results 
Characterization of the CHO-TSHr cell clones JPO9 and 
JP26 
We compared bTSH binding and CAMP production in the 
CHO wild-type cells and the CHO-TSHr cell clones, JP26 and 
JP09. Specific [ 1251]bTSH binding was less than 1% to CHO 
cells, 5-7% to JP26 cells, and 26-30% to JP09 cells. Displace- 
ment by increasing concentrations of unlabeled bTSH and 
Scatchard analysis of the data revealed that JP09 cells had a 
much higher bTSH-binding capacity than JP26 cells (Fig. la). 
The difference in the binding capacity of the clones was 
apparently related to the number of hTSHr expressed per 
cell, which was estimated to be 34,000 in JP09 and 2,000 in 
JP26 cells (Fig. la). Basal CAMP activity and bTSH-stimulated 
CAMP production were higher in JP09 cells than in JP26 cells. 
The ratio of maximum bTSH stimulation to basal activity, 
however, was lower in JP09 than in JP26 cells (-45 VS. 67; Fig. 
lb). The wild-type cells, as expected, were unresponsive to 
bTSH stimulation (data not shown). 
Responses of the CHO-TSHr cell clones JPO9 and JP26 to 
hCG and asialo-hCG 
We assessed the inhibition of [‘251]bTSH binding to CHO- 
TSHr JP09 and JP26 cells by hCG and asialo-hCG. Although 
hCG itself displayed little binding-inhibiting activity in ei- 
ther cell clone, asialo-hCG was much more potent in this 
respect; its ID,, was 20 mg/L (5.8 X 10e7 mol/L) in JP09 cells 
and 7 mg/L (2.0 X 10P7 mol/L) in JP26 cells (Fig. 2a). With 
respect to CAMP activation, a significant (P < 0.01, combined 
data from three closely concurring experiments with tripli- 
cate determinations), although not very impressive, CAMP 
increase over basal values in response to hCG stimulation 
was observed in JP09 cells, whereas little if any stimulation 
was seen in JP26 cells (Fig. 2b). The difference in the response 
of the two clones was more pronounced when cells were 
stimulated with asialo-hCG (Fig. 2b). Asialo-hCG stimulated 
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FIG. 1. bTSH binding (a; Scatchard plots) and CAMP stimulation by 
bTSH (b) in two different clones, JPO9 and JP26, of CHO cells ex- 
pressing hTSHr. JPO9 cells displayed a markedly higher binding 
capacity than JP26 cells. Because cell number, DNA content, amount 
of protein, and affinity for hTSHr were comparable in these experi- 
ments, the difference in binding capacity was attributable to the 
number of hTSHr expressed per cell. This was estimated to be 34,000 
in JPO9 and 2,000 in JP26 cells. The inset shows the plot for JP26 cells 
with an expanded scale. Consistent with their increased receptor 
number, CAMP production was higher in JPO9 cells. The ratio of basal 
to bTSH-stimulated values, however, was higher in JP26 cells. The 
values shown represent the means of closely concurring duplicate 
determinations for specific 1 ‘2611bTSH binding and the mean +- SD (n 
= 3) for CAMP determinations. The marked differences between the 
two cell clones shown here have been a constant finding in three 
separate experiments. 
JP09 cells up to 12-fold and JP26 cells 4-fold over basal values. 
For comparison, maximum bTSH stimulation in the same 
experiment was 45-fold in JP09 cells and 67-fold in JP26 cells. 
Maximum stimulation by asialo-hCG amounted to 30% of 
that induced by bTSH in the same experiment in JP09 cells, 
but was less than 6% of the bTSH values in JP26 cells. 
Thyrotropic activity of hCG isoforms in CHO-TSHr cells 
Next, the in vitro thyrotropic potencies of hCG isoforms 
derived from pregnancy and molar hCG were assessed in 
CHO-TSHr JP09 cells. Pool II (~14.1-5) and pool III (p1 >5) 
derived from hCGp were more active than pool I (~13.9-4.1) 
of hCGp in terms of the ability to both inhibit [‘2511bTSH 
binding and stimulate CAMP production (Fig. 3). Similarly, 
in the pools obtained from hCGm, a more alkaline p1 was 
associated with increased thyrotropic activity (Fig. 3). When 
comparing hCGp and hCGm, on the other hand, the presence 
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FIG. 2. Inhibition of [1251]bTSH binding (a) and stimulation of CAMP 
activitv Ib) in JPO9 and JP26 cells bv hCG and asialo-hCG. hCG shows 
a weak activity to inhibit [‘251]bTSk binding to both cells, and asialo- 
hCG is much more active in this respect. With respect to CAMP 
activation, JPO9 cells were more responsive to stimulation by hCG or 
asialo-hCG than JP26 cells. Maximum stimulation by asialo-hCG 
amounted to 30% of that induced by bTSH in JPO9 cells and to only 
6% in JP26 cells. For hCG, a similar estimate could be obtained only 
in JPO9 cells, because no appreciable hCG stimulation was observed 
in JP26 cells. The CAMP released by hCG was approximately 5% the 
amount of CAMP released by bTSH in JPO9 cells. The values shown 
represent the means of closely concurring duplicates for specific bind- 
ing data and the mean ? SD (n = 3) for CAMP determinations. The data 
shown in this figure were confirmed in two other experiments. 
of alkaline isoforms was about the same in the two prepa- 
rations (Fig. 3, inset), and the CAMP-stimulating activity in 
CHO-TSHr cells was also similar (data not shown). The cor- 
responding pools derived from hCGp or hCGm also did not 
differ in potency to bind to and stimulate CAMP release from 
CHO-TSHr cells (Fig. 3). 
Role of carbohydrate in hCG for hTSHr binding and CAMP 
stimulation in CHO-TSHr cells 
The immunological activities of hCG, asialo-hCG, asia- 
loagalacto-hCG, and deglycosylated hCG preparations em- 
ployed in these studies were assessed by a specific holo-hCG 
assay and found to be comparable (data not shown). 
As shown earlier, hCG itself showed little ability to inhibit 
[iz51]bTSH binding to CHO-TSHr cells (JPO9), and desialy- 
lation of hCG resulted in a marked enhancement of its ac- 
tivity. Removal of additional galactose residues, on the other 
hand, caused only a minor increase in the affinity of hTSHr 
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FIG. 3. Inhibition of [12511bTSH binding (a) and stimulation of CAMP 
activity (b) in CHO-TSHr JPO9 cells by hCG isoforms derived from 
pregnancy (hCGp) or molar hCG (hCGm). The isoforms contained in 
hCGp and hCGm were visualized by isoelectric focusing (see inset) 
and fractionated into three pools by cathion exchange chromatogra- 
phy: pool I comprising the p1 forms from ~13.9-4.1, pool II from p1 
4.1-5.0, and pool III with p1 above 5.0. The indices p and m indicate 
the origin of the pool from either hCGp or hCGm. The thyrotropic 
activities of the pools appear to be related to their p1 values, but 
unrelated to their origin from hCGp or hCGm. The values shown 
represent the means of closely concurring duplicates for specific bind- 
ing data and the mean ? SD (n = 3) for CAMP determinations. The 
differences in [1251]bTSH binding inhibition and CAMP stimulatory 
activity between the pools shown were the same as those observed in 
two other experiments. 
for the modified hormone, as judged from its ability to inhibit 
[‘2511bTSH binding. Nearly totally deglycosylated hCG was 
intermediate to asialoagalacto-hCG and asialo-hCG in this 
respect (Fig. 4a). With respect to the functional activation of 
hTSHr by these ligands, asialo-hCG was clearly the most 
potent form of hCG, although its potency, when tested in the 
same experiment, approached only approximately 30% the 
activity of bTSH (100 IU/L). Asialoagalacto-hCG and de- 
glycosylated hCG, on the other hand, were considerably less 
active as stimulators of CAMP release in CHO-TSHr cells 
than asialo-hCG, but still more active than hCG itself, which 
was the least effective agent (Fig. 4b). 
Discussion 
The occurrence of hyperthyroidism in patients with tro- 
phoblastic tumors and some cases of normal pregnancy may 
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FIG. 4. Inhibition of [1251]bTSH binding (a) and stimulation of CAMP 
activity(b) in CHO-TSHr JPO9 cells by the hCG variants asialo-hCG, 
asialoagalacto-hCG, and deglycosylated hCG. Removal of sialic acid 
from hCG markedly enhances both the affinity to hTSHr and the 
intrinsic activity of the hormone, whereas removal of further carbo- 
hydrates, although slightly favoring receptor binding, impairs recep- 
tor activation. At the maximum concentration tested (100 IU/L), 
bTSH released 1600 nmol/L CAMP (not shown). Eachpoint represents 
the mean of closely concurring duplicates for specific binding data and 
the mean -+ SD (n = 3) for CAMP determinations in a single experi- 
ment, and the results concur closely with those obtained in two other 
experiments. 
be explained by stimulation of the thyroid gland by hCG, 
which is present in exceedingly high concentrations in the 
circulation of these patients; a distinct molecular variant 
form of hCG with increased thyrotropic activity produced by 
the trophoblastic tumor or during pregnancy; or a combi- 
nation of the two factors (7). With respect to the in vitro 
thyrotropic activity of hCG, most investigators were unable 
to demonstrate significant stimulation of the CAMP response 
in human thyroid membranes (g-10,15). The same failure to 
stimulate CAMP activity in vitro has been observed in a hu- 
man thyroid carcinoma cell line (HTC) expressing the re- 
combinant hTSHr, but lacking endogenous hTSHr (11). In 
thyroid cells of rodent origin, on the other hand, including 
FRTL-5 cells and CHO cells transfected with the hTSHr, hCG 
has been shown to readily evoke significant CAMP responses 
(10, 18, 26-30). Clearly, the discrepancies seemed too 
pronounced to be explained by the use of different assay 
conditions. 
To seek possible explanations for the variation observed in 
the thyroid response to hCG, we studied two clones of CHO 
cells that had been stably transfected with hTSHr. Remark- 
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ably, the CAMP responses to hCG and its variant form asialo- 
hCG differed widely between the two clones. Although clone 
JP26 showed little, if any, response, clone JP09 was readily 
stimulated by hCG to release CAMP, with 1 IU of the hor- 
mone displaying a potency equivalent to 5 X lO-‘j IU bTSH. 
A similar thyrotropic activity of hCG has recently been re- 
ported by Yoshimura et al. (301, who used the same cell line. 
The difference between the two cell clones in their response 
to asialo-hCG, which was a more potent stimulator of CHO- 
TSHr cells than hCG, was even more striking. Interestingly, 
in our studies, the hCG responsiveness of the two CHO cell 
clones appeared not to parallel their bTSH sensitivity. This 
conclusion was further supported by the finding that CAMP 
production by asialo-hCG approached 30% that of bTSH in 
JP09 cells, but less than 6% that in JP26 cells. Both clones were 
extremely sensitive to stimulation by bTSH, with a response 
induced by a concentration as low as 0.001 IU/L (0.89 
pmol/L) being readily distinguishable from basal activity. 
For comparison, in HTC-TSHr cells, the limit of detection 
was about 0.1 IU/L bTSH (11). The variation observed in the 
responses to the various stimulators of the two CHO cell 
clones expressing hTSHr was surprising. It may be accounted 
for by differences in the expression of hTSHr in the two 
clones. In this respect, the binding studies we conducted 
indicated a number of hTSHr per cell in the physiological 
range in JP26 cells, whereas hTSHr density in JP09 cells was 
more than 10 times higher than that in normal human thy- 
rocytes (31). The possibility that CAMP stimulation was af- 
fected in part by a stimulation of endogenous hCG/LH re- 
ceptors could be excluded, because CHO wild-type cells 
were not stimulated by hCG or asialo-hCG. 
Another interesting aspect of the study relates to the role 
of carbohydrate in the thyrotropic activity of hCG in CHO- 
TSHr cells, which was strikingly different from that previ- 
ously reported in human assay systems. In human thyroid 
membranes or cells, including HTC cells expressing hTSHr 
(32), desialylated variants of hCG, although exhibiting mark- 
edly increased affinity for hTSHr, were devoid of intrinsic 
activity and acted as pure antagonists (11, 15, 17,33, 34). In 
contrast, in CHO-TSHr cells, desialylation of hCG resulted in 
a marked increase in both its affinity for hTSHr and its 
CAMP-stimulating activity. This was true for less sialylated 
isoforms of hCG and enzymatically desialylated hCG. Also, 
the effect was more pronounced in JP09 cells, which express 
an exceedingly high receptor density, than in JP26 cells. 
Cleavage of further carbohydrate, such as galactose, and 
removal of nearly the total carbohydrate moiety, on the other 
hand, although slightly improving receptor recognition, ex- 
erted a detrimental influence on intrinsic activity in JP09 
cells, although asialoagalacto-hCG and deglycosylated hCG 
were still more active than hCG. Interestingly, JP09 cells 
closely resemble FRTL-5 cells in this respect, which we have 
previously shown to be stimulated by desialylated hCG 
variants (18). 
Consistent with these findings, the rodent thyroid has long 
been recognized to be more sensitive to stimulation by hCG 
and desialylated hCG than the human thyroid (10, 26). Ap- 
parently, the role of carbohydrate in signal transduction var- 
ies among cells that differentially express TSHr or different 
types of cells expressing TSHr. This may explain at least in 
part the divergent responses to carbohydrate-modified hCG 
forms observed in various cell lines. As for the CHO cells 
expressing hTSHr, although they provide one of the most 
sensitive tools currently available for measuring thyroid 
stimulators, their nonthyroid nonhuman descent and the 
supraphysiological hTSHr number expressed emphasize the 
fact that any conclusions about the physiological significance 
of the findings derived from CHO cells should be drawn with 
caution. For that reason, at the present time it is not possible 
to resolve, on the basis of these studies, the ongoing contro- 
versy of whether hCG is indeed a thyroid stimulator of 
significant potency in man. The present findings provide a 
strong support in favor of the use of human thyroid cell lines, 
such as HTC, for hTSHr expression studies. 
With respect to the existence of molecular forms of hCG 
with increased thyrotropic activity, the present study re- 
vealed a variation in thyrotropic activity among the micro- 
heterogeneous isoforms of hCG (35, 36). It is important to 
note that this study, unlike previous studies by Pekary et al. 
(37) and Yoshimura et al. (381, focused on the isohormones of 
hCG and did not include variant forms of hCG or fragments 
thereof, which are known to be present in pregnancy urine 
or placental tissue extracts. These researchers reported an 
increased in vitro thyrotropic activity of partially sialated 
hCG variants extracted from hydatidiform moles of hyper- 
thyroid patients (37). In contrast to their material, our molar 
hCG was derived from euthyroid patients. The present stud- 
ies revealed a relation between the p1 value of the hCG 
molecules and their thyrotropic activity in CHO-TSHr JP09 
cells, with alkaline isoforms displaying an enhanced po- 
tency. This was true for hCG of both pregnancy and molar 
origin. On the other hand, we found no major differences 
between the activities of molar hCG and pregnancy hCG or 
between the isoforms of identical p1 derived from hCGp or 
hCGm. We conclude that, apart from tumor-derived hCG 
variants, which may be either highly acidic or basic forms of 
hCG (37-39), the hCG molecule itself is made up of isohor- 
mones that differ in their thyrotropic activity, and even sub- 
tle changes in the p1 spectrum of hCG may affect its thyro- 
tropic activity. 
In conclusion, both the differential expression of hTSHr 
and the intrinsic microheterogeneity of the hormone cause a 
variation in the CAMP response to hCG in CHO-TSHr cells. 
Both mechanisms may at least in part explain previous ob- 
servations that the hCG response differs among thyroid cells, 
particularly when they are derived from different species, 
and that the correlation between serum hCG concentrations 
and thyroid hormone levels in patients with trophoblast 
disease has been generally found to be poor (10,39-42). They 
may also play a role in modulating the thyroid response to 
hCG during pregnancy or trophoblast disease. 
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